Coronavirus immunogenic compositions and uses thereof
AssigneeAltimmune Inc.
InventorsBertrand Victor Gilbert Georges, M. Scot Roberts
Life of this patent
Estimating the term…
Abstract
Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal.
Claims33
An immunogenic composition comprising a replication defective adenoviral (rdAd) vector, wherein the rdAd vector is selected from:
- a) an rdAd vector comprising an expression cassette comprising a SARS-CoV-2 antigen coding sequence encoding at least one SARS-CoV-2 antigen, optionally wherein said antigen comprises a SARS-CoV-2 spike (S) protein receptor binding domain (RBD);
- said immunogenic composition being configured to induce neutralizing antibody and/or cellular immune response against SARS-CoV-2 in a mammalian subject to which said immunogenic composition is administered.
(canceled)
(canceled)
12-15. (canceled)
(canceled)
(canceled)
21-23. (canceled)
25-27. (canceled)
29-35. (canceled)
(canceled)
(canceled)
40-43. (canceled)
47-53. (canceled)
A method of treating or inhibiting the symptoms of a respiratory viral infection in a mammal, said respiratory viral infection causing elevated expression of interleukin-6 (IL-6), interleukin-1-alpha (IL-1α) and/or interleukin-12 (IL-12) in the lung of said mammal, the method comprising:
- intranasally administering an effective amount of an E1 and E3 deleted adenoviral vector, with or without expressing a SARS-CoV-2 antigen, to the subject, whereby expression of IL-6, IL-1α, and/or IL-12 in the lung is reduced thereby alleviating said symptoms for up to about 28 days following administration of the vector.
55-92. (canceled)
Dependencies are inferred from the claim text.